L 10
Latest Information Update: 24 Oct 2021
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors; Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 13 Oct 1999 New profile
- 13 Oct 1999 Preclinical development for Prostate cancer in USA (Unknown route)